OncLive
@onclive.bsky.social
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous #OvarianCancer #oncology #cancercare
www.onclive.com/view/pd-l1-e...
www.onclive.com/view/pd-l1-e...
www.onclive.com
January 27, 2026 at 9:47 PM
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous #OvarianCancer #oncology #cancercare
www.onclive.com/view/pd-l1-e...
www.onclive.com/view/pd-l1-e...
BREAKING 🚨: @fda.gov Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma #mmsm #Oncology
Learn more 📰: onclive.com/view/fda-app...
Learn more 📰: onclive.com/view/fda-app...
January 27, 2026 at 7:55 PM
BREAKING 🚨: @fda.gov Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma #mmsm #Oncology
Learn more 📰: onclive.com/view/fda-app...
Learn more 📰: onclive.com/view/fda-app...
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma #oncology #RCC #RMC
www.onclive.com/view/meta-an...
www.onclive.com/view/meta-an...
www.onclive.com
January 27, 2026 at 7:14 PM
Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma #oncology #RCC #RMC
www.onclive.com/view/meta-an...
www.onclive.com/view/meta-an...
@foxchasecancer.bsky.social Study Finds Radiation Therapy Administered Before Surgery Rarely Shrinks Retroperitoneal Sarcoma Tumors
#scmsm #oncology
www.onclive.com/view/study-f...
#scmsm #oncology
www.onclive.com/view/study-f...
www.onclive.com
January 27, 2026 at 6:59 PM
@foxchasecancer.bsky.social Study Finds Radiation Therapy Administered Before Surgery Rarely Shrinks Retroperitoneal Sarcoma Tumors
#scmsm #oncology
www.onclive.com/view/study-f...
#scmsm #oncology
www.onclive.com/view/study-f...
GLORA-4 Set to Evaluate Lisaftoclax Plus Azacitidine in Higher-Risk MDS in First-of-Its-Kind Study @mdanderson.bsky.social #hematology #oncology
www.onclive.com/view/glora-4...
www.onclive.com/view/glora-4...
www.onclive.com
January 27, 2026 at 1:13 PM
GLORA-4 Set to Evaluate Lisaftoclax Plus Azacitidine in Higher-Risk MDS in First-of-Its-Kind Study @mdanderson.bsky.social #hematology #oncology
www.onclive.com/view/glora-4...
www.onclive.com/view/glora-4...
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer @stolaney1.bsky.social @danafarber.bsky.social #bcsm www.onclive.com/view/fda-app...
www.onclive.com
January 27, 2026 at 12:16 AM
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer @stolaney1.bsky.social @danafarber.bsky.social #bcsm www.onclive.com/view/fda-app...
Real-World SEER Data Highlight Age-Related Survival Gap in ICI-Treated Advanced RCC #kcsm #oncology
www.onclive.com/view/real-wo...
www.onclive.com/view/real-wo...
www.onclive.com
January 26, 2026 at 3:00 PM
Real-World SEER Data Highlight Age-Related Survival Gap in ICI-Treated Advanced RCC #kcsm #oncology
www.onclive.com/view/real-wo...
www.onclive.com/view/real-wo...
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer #pancsm #oncology www.onclive.com/view/nalirif...
www.onclive.com
January 26, 2026 at 2:52 PM
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer #pancsm #oncology www.onclive.com/view/nalirif...
Watch Pooja Phull, MD, discuss the implications of a study showing how butyrate loss may affect post-transplant outcomes in patients with multiple myeloma. And check out our site for more insights from Dr Phull! #mmsm #hematology
www.onclive.com/view/microbi...
www.onclive.com/view/microbi...
January 23, 2026 at 11:04 PM
Watch Pooja Phull, MD, discuss the implications of a study showing how butyrate loss may affect post-transplant outcomes in patients with multiple myeloma. And check out our site for more insights from Dr Phull! #mmsm #hematology
www.onclive.com/view/microbi...
www.onclive.com/view/microbi...
A Guide to Interviewing for Hematology/Oncology Fellowship From a Chief Fellow @weillcornell.bsky.social #oncology #oncologyfellowship
www.onclive.com/view/a-guide...
www.onclive.com/view/a-guide...
www.onclive.com
January 23, 2026 at 9:42 PM
A Guide to Interviewing for Hematology/Oncology Fellowship From a Chief Fellow @weillcornell.bsky.social #oncology #oncologyfellowship
www.onclive.com/view/a-guide...
www.onclive.com/view/a-guide...
Unpacking the FDA Approvals That Reshaped Cancer Care in 2025 #oncology #FDA #bcsm #lcsm #GIcancer
www.onclive.com/view/unpacki...
www.onclive.com/view/unpacki...
www.onclive.com
January 23, 2026 at 7:37 PM
Nogapendekin Alfa Inbakicept Plus NK Cell Therapy Yields Strong OS Signal in Recurrent Glioblastoma #oncology #glioblastoma
www.onclive.com/view/nogapen...
www.onclive.com/view/nogapen...
www.onclive.com
January 23, 2026 at 7:36 PM
Nogapendekin Alfa Inbakicept Plus NK Cell Therapy Yields Strong OS Signal in Recurrent Glioblastoma #oncology #glioblastoma
www.onclive.com/view/nogapen...
www.onclive.com/view/nogapen...
Immune-Targeting Vaccine Shows Promise Intercepting Cancer in Patients With Lynch Syndrome @mdanderson.bsky.social #oncology
www.onclive.com/view/immune-...
www.onclive.com/view/immune-...
www.onclive.com
January 23, 2026 at 4:23 PM
Immune-Targeting Vaccine Shows Promise Intercepting Cancer in Patients With Lynch Syndrome @mdanderson.bsky.social #oncology
www.onclive.com/view/immune-...
www.onclive.com/view/immune-...
CBP/p300 Inhibition Expands Beyond Hematology Field to Show Efficacy in Solid Tumors #oncology www.onclive.com/view/cbp-p30...
www.onclive.com
January 23, 2026 at 4:12 PM
CBP/p300 Inhibition Expands Beyond Hematology Field to Show Efficacy in Solid Tumors #oncology www.onclive.com/view/cbp-p30...
NALIRIFOX Remains Effective Despite Dose Modification in First-Line PDAC @mdanderson.bsky.social @weillcornell.bsky.social @mayocliniccancer.bsky.social #oncology #pancreaticcancer #PDAC
www.onclive.com/view/nalirif...
www.onclive.com/view/nalirif...
www.onclive.com
January 23, 2026 at 1:20 PM
NALIRIFOX Remains Effective Despite Dose Modification in First-Line PDAC @mdanderson.bsky.social @weillcornell.bsky.social @mayocliniccancer.bsky.social #oncology #pancreaticcancer #PDAC
www.onclive.com/view/nalirif...
www.onclive.com/view/nalirif...
GDF-15 Blockade May Deepen Neoadjuvant IO Response in Cisplatin-Ineligible MIBC @myesmo.bsky.social #blcsm #oncology www.onclive.com/view/gdf-15-...
www.onclive.com
January 22, 2026 at 8:07 PM
GDF-15 Blockade May Deepen Neoadjuvant IO Response in Cisplatin-Ineligible MIBC @myesmo.bsky.social #blcsm #oncology www.onclive.com/view/gdf-15-...
ILUSTRO Trial Signals Role for First-Line Zolbetuximab-Based Triplet for Biomarker-Selected Gastric Cancer @orlandohealth.bsky.social #oncology #gcsm
www.onclive.com/view/ilustro...
www.onclive.com/view/ilustro...
www.onclive.com
January 22, 2026 at 7:13 PM
ILUSTRO Trial Signals Role for First-Line Zolbetuximab-Based Triplet for Biomarker-Selected Gastric Cancer @orlandohealth.bsky.social #oncology #gcsm
www.onclive.com/view/ilustro...
www.onclive.com/view/ilustro...
@foxchasecancer.bsky.social Center Announces Strategic Partnership with @spot_it_early Bolstering the Validity of its Breakthrough Early Cancer Detection Technology
#oncology #cancercare
www.onclive.com/view/fox-cha...
#oncology #cancercare
www.onclive.com/view/fox-cha...
www.onclive.com
January 22, 2026 at 5:58 PM
@foxchasecancer.bsky.social Center Announces Strategic Partnership with @spot_it_early Bolstering the Validity of its Breakthrough Early Cancer Detection Technology
#oncology #cancercare
www.onclive.com/view/fox-cha...
#oncology #cancercare
www.onclive.com/view/fox-cha...
WATCH 👀: Paolo Tarantino, MD, PhD, Laura Alder, MD, and Eric Singhi, MD, share more insight on what went down at Bridging the Gaps in Brain Mets.
#lcsm #bcsm #btsm #oncology
@danafarber.bsky.social @mdanderson.bsky.social @dukecancer.bsky.social
See video here ➡️: www.onclive.com/shorts/quick...
#lcsm #bcsm #btsm #oncology
@danafarber.bsky.social @mdanderson.bsky.social @dukecancer.bsky.social
See video here ➡️: www.onclive.com/shorts/quick...
www.onclive.com
January 22, 2026 at 5:08 PM
WATCH 👀: Paolo Tarantino, MD, PhD, Laura Alder, MD, and Eric Singhi, MD, share more insight on what went down at Bridging the Gaps in Brain Mets.
#lcsm #bcsm #btsm #oncology
@danafarber.bsky.social @mdanderson.bsky.social @dukecancer.bsky.social
See video here ➡️: www.onclive.com/shorts/quick...
#lcsm #bcsm #btsm #oncology
@danafarber.bsky.social @mdanderson.bsky.social @dukecancer.bsky.social
See video here ➡️: www.onclive.com/shorts/quick...
FDA Approves Guardant360 as Encorafenib Companion Diagnostic in BRAF V600E-Mutant mCRC #oncology #CRC
www.onclive.com/view/fda-app...
www.onclive.com/view/fda-app...
www.onclive.com
January 22, 2026 at 4:17 PM
FDA Approves Guardant360 as Encorafenib Companion Diagnostic in BRAF V600E-Mutant mCRC #oncology #CRC
www.onclive.com/view/fda-app...
www.onclive.com/view/fda-app...
INAVO123 Set to Determine Upfront Role of Inavolisib in PIK3CA-Mutant, HR+ Breast Cancer @uclahealth.org #oncology #bcsm
www.onclive.com/view/inavo12...
www.onclive.com/view/inavo12...
www.onclive.com
January 22, 2026 at 3:12 PM
INAVO123 Set to Determine Upfront Role of Inavolisib in PIK3CA-Mutant, HR+ Breast Cancer @uclahealth.org #oncology #bcsm
www.onclive.com/view/inavo12...
www.onclive.com/view/inavo12...
Treatment Individualization Is Increasingly Vital With T-DXd Poised to Enter Early-Stage HER2+ Breast Cancer Paradigm #bcsm #oncology www.onclive.com/view/treatme...
www.onclive.com
January 22, 2026 at 2:06 PM
Treatment Individualization Is Increasingly Vital With T-DXd Poised to Enter Early-Stage HER2+ Breast Cancer Paradigm #bcsm #oncology www.onclive.com/view/treatme...
WATCH 👀: Jason Mouabbi, MD, Manmeet Ahluwalia, MD, MBA, FASCO, and Laura Alder, MD discuss the key takeaways from Bridging the Gaps in Brain Mets.
@baptisthealthjx.bsky.social @mdanderson.bsky.social @dukecancer.bsky.social
Watch here ➡️: www.onclive.com/shorts/bridg...
#bcsm #lcsm #btsm
@baptisthealthjx.bsky.social @mdanderson.bsky.social @dukecancer.bsky.social
Watch here ➡️: www.onclive.com/shorts/bridg...
#bcsm #lcsm #btsm
www.onclive.com
January 21, 2026 at 11:59 PM
WATCH 👀: Jason Mouabbi, MD, Manmeet Ahluwalia, MD, MBA, FASCO, and Laura Alder, MD discuss the key takeaways from Bridging the Gaps in Brain Mets.
@baptisthealthjx.bsky.social @mdanderson.bsky.social @dukecancer.bsky.social
Watch here ➡️: www.onclive.com/shorts/bridg...
#bcsm #lcsm #btsm
@baptisthealthjx.bsky.social @mdanderson.bsky.social @dukecancer.bsky.social
Watch here ➡️: www.onclive.com/shorts/bridg...
#bcsm #lcsm #btsm
HS-20093 Shows Promising Activity in Relapsed/Refractory Sarcoma #oncology #sarcoma
www.onclive.com/view/hs-2009...
www.onclive.com/view/hs-2009...
www.onclive.com
January 21, 2026 at 3:32 PM
HS-20093 Shows Promising Activity in Relapsed/Refractory Sarcoma #oncology #sarcoma
www.onclive.com/view/hs-2009...
www.onclive.com/view/hs-2009...
Mezigdomide-Based Triplet Highlights Potential of CELMoDs in Myeloma Management @rahulbanerjeemd.bsky.social #mmsm #oncology www.onclive.com/view/mezigdo...
www.onclive.com
January 21, 2026 at 2:54 PM
Mezigdomide-Based Triplet Highlights Potential of CELMoDs in Myeloma Management @rahulbanerjeemd.bsky.social #mmsm #oncology www.onclive.com/view/mezigdo...